Evidence map›Paper›PMID 34435876›Full record

ArticleFuture oncology (London, England)2021

Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.

Alexander R Gupta, Gavitt A Woodard, David M Jablons, Michael J Mann, Johannes R Kratz

Open access · hybridAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alexander R GuptaDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-2813-6175
Gavitt A WoodardDepartment of Surgery, Yale School of Medicine, New Haven, CT 06510, USA.
David M JablonsDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Michael J MannDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Johannes R KratzDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
University of California, San Francisco · USYale University · US

Funding

Filling a Void of Research (FAVOR) Training for Transplant SurgeonsT32AI125222 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER G STOCK, Minnie M Sarwal · 2016 to 2026
$3.4M
NIAID NIH HHS T32 AI125222
6 · The paper itself

Abstract

There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as 'early stage.' A 14-gene quantitative PCR-based expression profile has been extensively validated to better identify patients at high-risk of 5-year mortality after surgical resection than conventional staging - mortality that almost always results from previously undetectable metastases. Furthermore, prospective studies now suggest a predictive benefit in disease-free survival when the assay is used to guide adjuvant chemotherapy decisions in early-stage non-small-cell lung cancer patients.

Indexed as

Biomarkers, TumorCarcinogenesisCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantClinical Decision-MakingDatasets as TopicDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsMolecular Diagnostic TechniquesNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyProspective StudiesBiomarkers, Tumoradjuvant therapymolecular assaymolecular prognostic classifiernon-small-cell lung cancerpredictiverisk stratificationtumor genetic profile

Identifiers

PMID34435876
PMCPMC9039775
OpenAlexW3194240398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.